Wockhardt adds another 8,700 bottles to Toprol recall; ABPI board clears Novo employees after complaint;

@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Report | Follow @FiercePharma

@TracyStaton: Would you pay $84K for Sovaldi yourself if you had hep C? Check out this discussion FiercePharma's LinkedIn group. More | Follow @TracyStaton

@EricPFierce: Interesting dissection of Valeant's 'opaque' biz model from ProPublica's Jesse Eisinger. Story | Follow @EricPFierce

@CarlyHFierce: Russia mulls taking $300M in state vaccine contracts local. FierceVaccines story | Follow @CarlyHFierce

@JustinHFierce: Zoetis Animal Health $ZTS traded up 0.35% during mid-day and hit $31.36, upgraded by Zacks from an underperform. More | Follow @JustinHFierce

> India's Wockhardt issued yet another recall of generic Toprol XL, pulling more than 8,000 bottles of the hypertension remedy because tablets failed a dissolution test. Report

> The Association of the British Pharmaceutical Industry's compliance watchdog cleared Novo Nordisk ($NVO) of any wrongdoing after investigating a complaint about three of its employees. Report

> Novo Nordisk ($NVO) said the government of Québec added Victoza, its GLP-1 diabetes treatment, to its reimbursement formulary. Release

> Ironwood Pharmaceuticals ($IRWD) chose Douglas Williams, EVP of research and development at Biogen Idec ($BIIB), to serve on its board of directors. Release

> As Nestlé moves more deeply into health-related products that require big investments in development, it's less tolerant of its low-performing food brands. Report

> The Chinese drugmaker Kangmei Pharma plans to plow 800 million yuan ($128 million) into a ginseng project. Report

Medical Device News

@FierceMedDev: Medtronic considers bid for Smith & Nephew amid building med dev merger mania. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Surgical instruments that improve cellulite will get FDA downgrade. Article | Follow @VarunSaxena2

@MichaelGFierce: Singapore team designs nanotechnology glaucoma treatment for sustained release. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Mind-controlled exoskeleton with a 3D-printed helmet could make its debut at the World Cup opening ceremony. Story from The Atlantic | Follow @EmilyWFierce

> Delaying valve replacement procedures could adversely impact high-risk patients. Article

> Study supports clinical guidelines on ICD usage. Story

Biotech News

@FierceBiotech: Join 's & 's today, 2pm ET for an chat. Follow . | Follow @FierceBiotech

@JohnCFierce: ICYMI yesterday: Trevi, Complexa bag $38M in VC cash to hit the gas on R&D. Story | Follow @JohnCFierce

@DamianFierce: Forgot @BayerHealthCare's pharma boss is leaving for International Flavors & Fragrances, which sounds like smthng RZA would boast of having. | Follow @DamianFierce

@EmilyMFierce: ICYMI: Nektar reports tumor reduction in preclinical study. Story from FierceBiotech Research | Follow @EmilyMFierce

> GlaxoSmithKline tees up another huge cardio PhIII after darapladib flop. Article

> Boehringer's IPF drug hits the EU fast track in race with InterMune. Story

> FierceBiotech and the experts weigh in on surviving the proof-of-concept challenge. Editor's Corner

> Analysts: Shire must go shopping to stay independent. Report

Vaccines News

> GAVI nets $50M for Merck's Gardasil, GSK's Cervarix. News

> Scripps, U. of Nebraska-Lincoln win $15M to advance HIV vaccines. Article

> PharmAthene anthrax vax aces survival in rabbit study. Item

> Study: Cholera vaccine has 86% effectiveness rate. Story

> Amgen to pursue T-Vec approval despite PhIII survival miss. More

Pharma Manufacturing News

> Vietnam bans products from 45 Indian companies for failing to meet standards. Item

> Turkey's drugmakers expand manufacturing as market booms. More

> Amneal said to be negotiating to buy Indian sterile injectable manufacturer. Report

> Glenmark opens new mAb manufacturing facility in Switzerland. Article

> AbbVie API expansion in Ireland readies it for anticipated hep C treatment. Story

And Finally... Should Apple ($AAPL) and Google ($GOOG) police the health-and-fitness apps sold via its marketplaces? Report

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.